Soligenix Inc
NASDAQ:SNGX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Soligenix Inc
Selling, General & Administrative
Soligenix Inc
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Soligenix Inc
NASDAQ:SNGX
|
Selling, General & Administrative
-$4.4m
|
CAGR 3-Years
13%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-2%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Selling, General & Administrative
-$14B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Selling, General & Administrative
-$5.7B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Selling, General & Administrative
-$6.9B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-4%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Selling, General & Administrative
-$1.8B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-17%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Selling, General & Administrative
-$3.3B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-15%
|
|
Soligenix Inc
Glance View
Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. The company is headquartered in Princeton, New Jersey and currently employs 13 full-time employees. The firm is focused on developing products to treat rare diseases. The firm operates through two segments: Specialized BioTherapeutics and Public Health Solutions. Specialized BioTherapeutics segments includes developing of HyBryte (SGX301 or synthetic hypericin) a photodynamic therapy for the treatment of cutaneous T-cell lymphoma (CTCL). Public Health Solutions segment includes RiVax to protect against exposure to ricin toxin vaccine candidate and SGX943 therapeutic candidate for antibiotic resistant and infectious disease. The firm's Development programs include innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of inflammatory diseases, oral mucositis in head and neck cancer, and oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders including pediatric Crohn's disease (SGX203).
See Also
What is Soligenix Inc's Selling, General & Administrative?
Selling, General & Administrative
-4.4m
USD
Based on the financial report for Dec 31, 2025, Soligenix Inc's Selling, General & Administrative amounts to -4.4m USD.
What is Soligenix Inc's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 10Y
-2%
Over the last year, the Selling, General & Administrative growth was -3%. The average annual Selling, General & Administrative growth rates for Soligenix Inc have been 13% over the past three years , -2% over the past five years , and -2% over the past ten years .
